ClinicalTrials.gg
CompletedNCT06135675Updated Apr 25, 2025Results posted

PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia

A Phase 1/2 interventional study of TNP-2092 capsules and Placebo in Hyperammonemia, sponsored by TenNor Therapeutics (Suzhou) Limited. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by TenNor Therapeutics (Suzhou) Limited · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Aug 2020, registered Nov 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this study was to evaluate the safety, tolerability, and pharmacokinetic characteristics of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia; and to preliminarily observe the effects of the study drug on blood ammonia and hepatic encephalopathy related clinical symptoms and signs, neuropsychological indicators, and quality of life in liver cirrhosis patients with hyperammonemia.

Read the detailed description

The aim of this study was to evaluate the safety, tolerability, and pharmacokinetic characteristics of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia; and to preliminarily observe the effects of the study drug on blood ammonia and hepatic encephalopathy related clinical symptoms and signs, neuropsychological indicators, and quality of life in liver cirrhosis patients with hyperammonemia.

A total of 3 dose groups will be set up, i.e., 100 mg BID, 300 mg BID and 600 mg BID groups. Drugs will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15. Each dose group will include a study drug TNP-2092 capsule arm and a placebo control arm. Subjects will exit upon completion of the safety and tolerability evaluation on D17.

Twelve liver cirrhosis patients with hyperammonemia are planned to be enrolled in each dose group. The 12 patients will be assigned in a ratio of 2:1 to the TNP-2092 capsule arm and the placebo arm, with 8 patients receiving TNP-2092 Capsules and 4 receiving placebos.

Enrollment for the second dose group may start only after the previous dose group has fully completed the treatment period and passed the safety and tolerability evaluation.

02

Conditions studied

  • Hyperammonemia

Browse trials for

03

In context

Hyperammonemia

25 studies on the registry are indexed under Hyperammonemia; 3 are open to participants now.

This study's enrollment of 36 is above the median of 31 across 16 interventional studies indexed under Hyperammonemia.

Browse Hyperammonemia studies →

Lead sponsor

TenNor Therapeutics (Suzhou) Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 (inclusive) years of age, male or female.
  • Clinically diagnosed with liver cirrhosis.
  • Fasting venous blood ammonia above (ULN).
  • Organ functions must meet the following criteria:
  • Peripheral blood: ≥ 0.5*109/L, ≥20*109/L, ≥ 8 g/dL.
  • Liver: (AST) and alanine aminotransferase (ALT) ≤ 5 × ULN; serum total (TBL) ≤ 5 × ULN.
  • Kidney: ≥ 60 mL/min.
  • No malabsorption or other gastrointestinal disorders that affect drug absorption.
  • Weight ≥ 45 kg and [BMI = weight (kg)/height 2 (m2) ] between 18 and 34 (inclusive) kg/m2.
  • Subjects (including their partners) will have no pregnancy plan and voluntarily take effective measures within 6 months after drug withdrawal. Refer to Appendix 9 for specific contraceptive measures.
  • Subjects or their legal representatives sign the Form and fully understand the content, procedures, and potential adverse reactions prior to the initiation of the study.
  • Able to complete the study per the requirements in the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Subjects who are allergic to rifamycin or quinolone antibacterial agents or those with an allergic constitution.
  • Pregnant or lactating women, or women of childbearing age with a positive pregnancy test from the screening period to initiation of the study treatment.
  • Subjects with serious nervous or mental disorders.
  • Subjects with class C liver cirrhosis.
  • Subjects with Grade 2 or above hepatic encephalopathy.
  • Subjects who have been diagnosed with Clostridium difficile-induced pseudomembranous enteritis within 3 months.
  • Subjects who have had systemic infection or gastrointestinal bleeding within 7 days prior to screening.
  • Subjects with abnormal clinical laboratory tests or other clinical findings indicative of clinically significant disorders that, in the opinion of the investigator, make them not eligible for this clinical study.
  • Subjects who have used sedatives, probiotics, cathartics or antibacterial agents within 7 days prior to screening.
  • Subjects who have used other study drugs or participated in other drug clinical trials within 1 month prior to screening.
  • Subjects need to use the following concomitant drugs during the study treatment period: cathartics and drugs for ammonia reduction listed in 5.2.1 in the Guidelines on the Management of Hepatic Encephalopathy in Liver Cirrhosis 2018 (e.g., lactulose, lactitol, L-ornithine L-aspartate(LOLA), rifaximin, other antibacterial agents, etc.) ; protease inhibitors (e.g., ritonavir boosted or non-boosted saquinavir, atazanavir, darunavir, fosamprenavir, tipranavir, etc.) ; praziquantel; halothane; class IA and III antiarrhythmics (disopyramide, procainamide, quinidine, amiodarone, dofetilide, dronedarone, ibutilide, sotalol, etc.) ; strong inhibitors and inducers of liver metabolic enzymes;
  • Positive HIV antigen/antibody screen; positive Treponema pallidum antibody screen requires the investigator's judgment with the consideration of Rapid plasma regain(RPR) results.
  • Positive urine drug screen or history of drug abuse within the past 5 years.
  • Positive alcohol breath test.
  • Acute diseases or concomitant medications from screening to study medication.
  • Other circumstances deemed by the investigator to be unsuitable for enrollment in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    TNP-2092 capsules 100mg Twice daily(BID)

    Subjects received TNP-2092 capsules orally twice daily at the dose of 100 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15.

    Drug: TNP-2092 capsules

  • Experimental
    TNP-2092 capsules 300mg BID

    Subjects received TNP-2092 capsules orally twice daily at the dose of 300 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15.

    Drug: TNP-2092 capsules

  • Experimental
    TNP-2092 capsules 600mg BID

    Subjects received TNP-2092 capsules orally twice daily at the dose of 600 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15.

    Drug: TNP-2092 capsules

  • Placebo comparator
    Placebo

    Subjects received TNP-2092 placebo capsules orally twice daily in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15.

    Drug: Placebo

Interventions

  • Administration orally.

    Also known as: Rifaquizinone capsules

  • DrugPlacebo

    Administration orally.

    Also known as: TNP-2092 placebo capsules

06

What researchers measure

Primary outcomes

  1. Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs)

    To investigate the safety and tolerability of TNP-2092 by assessment of the number of participants with AEs following administration of TNP-2092 capsules. An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to 17 days after the first dosing.

  2. Maximum Observed Plasma Concentration (Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia on Day 1.

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose

  3. Area Under the Plasma Concentration-time Curve From the Time of Administration to the Time of the Last Measurable Plasma Concentration (AUC0-last) on Day 1.

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose

  4. Area Under the Plasma Concentration-time Curve From the Time of Administration Extrapolated to Infinity (AUC0-∞) on Day 15

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose

  5. Time to Reach the Maximum Observed Plasma Concentration (Tmax) on Day 1

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose

  6. Maximum Observed Plasma Concentration (Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia on Day 15.

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose

  7. Area Under the Plasma Concentration-time Curve From the Time of Administration to the Time of the Last Measurable Plasma Concentration (AUC0-last) on Day 15.

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose

  8. Time to Reach the Maximum Observed Plasma Concentration (Tmax) Day 15

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose

  9. Area Under the Plasma Concentration-time Curve From the Time of Administration Extrapolated to Infinity (AUC0-∞) Day 1

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose

  10. Half Life (t1/2) of TNP-2092 Capsules on Day 1

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose

  11. Half Life (t1/2) of TNP-2092 Capsules on Day 15

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose

  12. Area Under the Plasma Concentration-time Curve Within a Dosing Interval (AUC0-tau) on Day 1

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose

  13. Area Under the Plasma Concentration-time Curve Within a Dosing Interval (AUC0-tau) on Day 15

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose

  14. Accumulation Index Rac(Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (Cmax) was calculated from the ratio of Cmax (Day 15) to Cmax (Day 1)

    Time frame: Day 1: 30-60 min prior to first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, and 12 h post-dose (prior to next dose). Day 15: 30-60 min pre-dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose.

  15. Accumulation Index Rac(AUC) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (AUC) was calculated from the ratio of AUC0-tau (Day 15) to AUC0-tau(Day 1).

    Time frame: Day 1: 30-60 min prior to first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, and 12 h post-dose (prior to next dose). Day 15: 30-60 min pre-dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose.

Secondary outcomes

  1. Changes in the Fasting Venous Blood Ammonia Concentration From Baseline (Mean Pre-treatment Measured)

    The changes in the fasting venous blood ammonia concentration from baseline will be compared with the placebo to evaluate the preliminary efficacy of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia.

    Time frame: Baseline and Day 15

  2. Proportion of Participants With Positive Result of Number Connection Test A (NCT-A)

    Evaluation of NCT-A is based on the time required to complete the test. The results will be positive according to following criteria: 1) the time is over 34.3 seconds while the age is less than 35 years; 2) the time is over 45.7 seconds while the age is between 35 to 44 years; 3) the time is over 52.8 seconds while age is between 45 to 54 years; 4) the time is over 61.9 seconds while the age is between 55 to 64 years. The positive result means a worse outcome.

    Time frame: Baseline, Day 7 and Day 15

  3. Proportion of Participants With Positive Result of Digital Symbol Test (DST)

    Evaluation of Digital symbol test (DST) is based on the score gained within 90 seconds, and the results are positive according to following criteria: 1) the score is less than 40.5 while the age is less than 35 years; 2) the score is less than 35.0 while the age is between 35 to 44 years; 3) the score is less than 28.5 while the age is between 45 to 54 years; 4) the score is less than 26.0 while the age is between 55 to 64 years. The positive result means a worse outcome.

    Time frame: Baseline, Day 7 and Day 15

  4. Changes in the Total Scores of Quality of Life (QOL) From Baseline

    Changes in the total scores of QOL from baseline will be compared with the placebo to evaluate the preliminary efficacy of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia. The range of QOL scores is 30 \~ 150. Patients with lower scores means a better outcome.

    Time frame: Baseline, Day 7 and Day 15

  5. Proportion of Participants Whose Asterixis is Elicited

    Asterixis is a physical exam finding that can be elicited by asking the participant to extend the arms, flex the wrists, and spread the fingers wide. Clinically, asterixis produces flapping tremors. In a flapping tremor, an participant will flap their wrists like a bird flapping its wings. Asterixis elicited means a worse outcome.

    Time frame: Baseline, Day 7 and Day 15

  6. Clinical Grade of Hepatic Encephalopathy

    Grade 0 of HE (without HE) is nomal, Grade 0 of HE (MHE) is alterations of brain function in neuropsychological or neurophysiological measures without clinical signs of HE, Grade 1 of HE is mild lack of awareness, Grade 2 of HE is lethargic, Grade 3 of HE is somnolent, and Grade 4 of HE is coma. Higher score means worse outcome.

    Time frame: Baseline, Day 7 and Day 15

  7. Areas Under the Blood Ammonia Concentration-time Curve

    Plasma concentrations of Blood Ammonia were measured by a specific and validated assay. Changes in the Fasting Venous Blood Ammonia Concentration From Baseline were used to measure AUC.

    Time frame: Baseline to Day 15

07

Results

Posted May 10, 2024

Participant flow

Participant flow — Overall Study
MilestoneTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDTNP-2092 Capsules Placebo
Started88812
Completed78811
Not completed1001

Outcome measures

PrimarySafety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs)

To investigate the safety and tolerability of TNP-2092 by assessment of the number of participants with AEs following administration of TNP-2092 capsules. An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to 17 days after the first dosing.
Reported as:
Number · participants
Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs)
participantsTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDPlacebo
Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs)6678
PrimaryMaximum Observed Plasma Concentration (Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia on Day 1.

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose
Reported as:
Mean · ng/ml
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia on Day 1.
ng/mlTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia on Day 1.90.4 ± 42.9140 ± 120415 ± 294
PrimaryArea Under the Plasma Concentration-time Curve From the Time of Administration to the Time of the Last Measurable Plasma Concentration (AUC0-last) on Day 1.

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose
Reported as:
Mean · h*ng/ml
Area Under the Plasma Concentration-time Curve From the Time of Administration to the Time of the Last Measurable Plasma Concentration (AUC0-last) on Day 1.
h*ng/mlTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Area Under the Plasma Concentration-time Curve From the Time of Administration to the Time of the Last Measurable Plasma Concentration (AUC0-last) on Day 1.309 ± 178524 ± 5371610 ± 1200
PrimaryArea Under the Plasma Concentration-time Curve From the Time of Administration Extrapolated to Infinity (AUC0-∞) on Day 15

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose
Reported as:
Mean · h*ng/ml
Area Under the Plasma Concentration-time Curve From the Time of Administration Extrapolated to Infinity (AUC0-∞) on Day 15
h*ng/mlTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Area Under the Plasma Concentration-time Curve From the Time of Administration Extrapolated to Infinity (AUC0-∞) on Day 15396 ± 257756 ± 5702680 ± 1790
PrimaryTime to Reach the Maximum Observed Plasma Concentration (Tmax) on Day 1

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose
Reported as:
Mean · h
Time to Reach the Maximum Observed Plasma Concentration (Tmax) on Day 1
hTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Time to Reach the Maximum Observed Plasma Concentration (Tmax) on Day 14.75 ± 0.465.13 ± 0.365.13 ± 0.35
PrimaryMaximum Observed Plasma Concentration (Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia on Day 15.

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose
Reported as:
Mean · ng/ml
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia on Day 15.
ng/mlTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia on Day 15.60.8 ± 28.5164 ± 118543 ± 420
PrimaryArea Under the Plasma Concentration-time Curve From the Time of Administration to the Time of the Last Measurable Plasma Concentration (AUC0-last) on Day 15.

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose
Reported as:
Mean · h*ng/ml
Area Under the Plasma Concentration-time Curve From the Time of Administration to the Time of the Last Measurable Plasma Concentration (AUC0-last) on Day 15.
h*ng/mlTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Area Under the Plasma Concentration-time Curve From the Time of Administration to the Time of the Last Measurable Plasma Concentration (AUC0-last) on Day 15.380 ± 247739 ± 5552610 ± 1730
PrimaryTime to Reach the Maximum Observed Plasma Concentration (Tmax) Day 15

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose
Reported as:
Mean · h
Time to Reach the Maximum Observed Plasma Concentration (Tmax) Day 15
hTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Time to Reach the Maximum Observed Plasma Concentration (Tmax) Day 154.43 ± 0.784.75 ± 0.464.50 ± 1.85
PrimaryArea Under the Plasma Concentration-time Curve From the Time of Administration Extrapolated to Infinity (AUC0-∞) Day 1

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose
Reported as:
Mean · h*ng/ml
Area Under the Plasma Concentration-time Curve From the Time of Administration Extrapolated to Infinity (AUC0-∞) Day 1
h*ng/mlTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Area Under the Plasma Concentration-time Curve From the Time of Administration Extrapolated to Infinity (AUC0-∞) Day 1332 ± 188561 ± 5651790 ± 1210
PrimaryHalf Life (t1/2) of TNP-2092 Capsules on Day 1

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose
Reported as:
Mean · h
Half Life (t1/2) of TNP-2092 Capsules on Day 1
hTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Half Life (t1/2) of TNP-2092 Capsules on Day 12.52 ± 0.632.23 ± 0.812.99 ± 2.29
PrimaryHalf Life (t1/2) of TNP-2092 Capsules on Day 15

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose
Reported as:
Mean · h
Half Life (t1/2) of TNP-2092 Capsules on Day 15
hTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Half Life (t1/2) of TNP-2092 Capsules on Day 158.17 ± 1.846.92 ± 2.637.93 ± 1.09
PrimaryArea Under the Plasma Concentration-time Curve Within a Dosing Interval (AUC0-tau) on Day 1

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration-time Curve Within a Dosing Interval (AUC0-tau) on Day 1
h*ng/mLTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Area Under the Plasma Concentration-time Curve Within a Dosing Interval (AUC0-tau) on Day 1309 ± 179525 ± 5381610 ± 1200
PrimaryArea Under the Plasma Concentration-time Curve Within a Dosing Interval (AUC0-tau) on Day 15

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration-time Curve Within a Dosing Interval (AUC0-tau) on Day 15
h*ng/mLTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Area Under the Plasma Concentration-time Curve Within a Dosing Interval (AUC0-tau) on Day 15303 ± 187646 ± 4662230 ± 1480
PrimaryAccumulation Index Rac(Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (Cmax) was calculated from the ratio of Cmax (Day 15) to Cmax (Day 1)

Time frame:
Day 1: 30-60 min prior to first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, and 12 h post-dose (prior to next dose). Day 15: 30-60 min pre-dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose.
Reported as:
Mean · ratio
Accumulation Index Rac(Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia
ratioTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Accumulation Index Rac(Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia0.74 ± 0.221.23 ± 0.491.26 ± 0.42
PrimaryAccumulation Index Rac(AUC) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (AUC) was calculated from the ratio of AUC0-tau (Day 15) to AUC0-tau(Day 1).

Time frame:
Day 1: 30-60 min prior to first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, and 12 h post-dose (prior to next dose). Day 15: 30-60 min pre-dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose.
Reported as:
Mean · ratio
Accumulation Index Rac(AUC) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia
ratioTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BID
Accumulation Index Rac(AUC) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia1.09 ± 0.401.38 ± 0.391.47 ± 0.55
SecondaryChanges in the Fasting Venous Blood Ammonia Concentration From Baseline (Mean Pre-treatment Measured)

The changes in the fasting venous blood ammonia concentration from baseline will be compared with the placebo to evaluate the preliminary efficacy of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia.

Time frame:
Baseline and Day 15
Reported as:
Mean · μmol/L
Changes in the Fasting Venous Blood Ammonia Concentration From Baseline (Mean Pre-treatment Measured)
μmol/LTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDPlacebo
Changes in the Fasting Venous Blood Ammonia Concentration From Baseline (Mean Pre-treatment Measured)5.7 ± 17.50-2.1 ± 22.49-14.1 ± 18.120.5 ± 45.29
SecondaryProportion of Participants With Positive Result of Number Connection Test A (NCT-A)

Evaluation of NCT-A is based on the time required to complete the test. The results will be positive according to following criteria: 1) the time is over 34.3 seconds while the age is less than 35 years; 2) the time is over 45.7 seconds while the age is between 35 to 44 years; 3) the time is over 52.8 seconds while age is between 45 to 54 years; 4) the time is over 61.9 seconds while the age is between 55 to 64 years. The positive result means a worse outcome.

Time frame:
Baseline, Day 7 and Day 15
Reported as:
Count of participants · Participants
Proportion of Participants With Positive Result of Number Connection Test A (NCT-A)
ParticipantsTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDPlacebo
Baseline66812
Day 776812
Day 1557811
SecondaryProportion of Participants With Positive Result of Digital Symbol Test (DST)

Evaluation of Digital symbol test (DST) is based on the score gained within 90 seconds, and the results are positive according to following criteria: 1) the score is less than 40.5 while the age is less than 35 years; 2) the score is less than 35.0 while the age is between 35 to 44 years; 3) the score is less than 28.5 while the age is between 45 to 54 years; 4) the score is less than 26.0 while the age is between 55 to 64 years. The positive result means a worse outcome.

Time frame:
Baseline, Day 7 and Day 15
Reported as:
Count of participants · Participants
Proportion of Participants With Positive Result of Digital Symbol Test (DST)
ParticipantsTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDPlacebo
Baseline4237
Day 74238
Day 150137
SecondaryChanges in the Total Scores of Quality of Life (QOL) From Baseline

Changes in the total scores of QOL from baseline will be compared with the placebo to evaluate the preliminary efficacy of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia. The range of QOL scores is 30 \~ 150. Patients with lower scores means a better outcome.

Time frame:
Baseline, Day 7 and Day 15
Reported as:
Mean · score on a scale
Changes in the Total Scores of Quality of Life (QOL) From Baseline
score on a scaleTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDPlacebo
Day 7-6.1 ± 5.646.4 ± 15.803.1 ± 13.910.5 ± 9.21
Day 15-3.0 ± 4.737.1 ± 15.824.6 ± 5.63-1.4 ± 15.88
SecondaryProportion of Participants Whose Asterixis is Elicited

Asterixis is a physical exam finding that can be elicited by asking the participant to extend the arms, flex the wrists, and spread the fingers wide. Clinically, asterixis produces flapping tremors. In a flapping tremor, an participant will flap their wrists like a bird flapping its wings. Asterixis elicited means a worse outcome.

Time frame:
Baseline, Day 7 and Day 15
Reported as:
Count of participants · Participants
Proportion of Participants Whose Asterixis is Elicited
ParticipantsTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDPlacebo
Whether asterixis is elicited at Baseline — Yes0000
Whether asterixis is elicited at Baseline — No88812
Whether asterixis is elicited on Day 7 — Yes0000
Whether asterixis is elicited on Day 7 — No88812
Whether asterixis is elicited on Day 15 — Yes0000
Whether asterixis is elicited on Day 15 — No88812
SecondaryClinical Grade of Hepatic Encephalopathy

Grade 0 of HE (without HE) is nomal, Grade 0 of HE (MHE) is alterations of brain function in neuropsychological or neurophysiological measures without clinical signs of HE, Grade 1 of HE is mild lack of awareness, Grade 2 of HE is lethargic, Grade 3 of HE is somnolent, and Grade 4 of HE is coma. Higher score means worse outcome.

Time frame:
Baseline, Day 7 and Day 15
Reported as:
Count of participants · Participants
Clinical Grade of Hepatic Encephalopathy
ParticipantsTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDPlacebo
Baseline — Grade 0 of HE (without HE)2200
Baseline — Grade 0 of HE (MHE)66812
Baseline — Grade 1 of HE0000
Baseline — Grade 2 of HE0000
Baseline — Grade 3 of HE0000
Baseline — Grade 4 of HE0000
Day 7 — Grade 0 of HE (without HE)1100
Day 7 — Grade 0 of HE (MHE)77812
Day 7 — Grade 1 of HE0000
Day 7 — Grade 2 of HE0000
Day 7 — Grade 3 of HE0000
Day 7 — Grade 4 of HE0000
Day 15 — Grade 0 of HE (without HE)1100
Day 15 — Grade 0 of HE (MHE)77812
Day 15 — Grade 1 of HE0000
Day 15 — Grade 2 of HE0000
Day 15 — Grade 3 of HE0000
Day 15 — Grade 4 of HE0000
SecondaryAreas Under the Blood Ammonia Concentration-time Curve

Plasma concentrations of Blood Ammonia were measured by a specific and validated assay. Changes in the Fasting Venous Blood Ammonia Concentration From Baseline were used to measure AUC.

Time frame:
Baseline to Day 15
Reported as:
Mean · h*μmol/L
Areas Under the Blood Ammonia Concentration-time Curve
h*μmol/LTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDPlacebo
Day 1481.6 ± 564.5480.2 ± 607.9225.0 ± 544.185.5 ± 999.3
Day 1-Day 15-1716.7 ± 5778.5-3205.4 ± 8311.8-5805.6 ± 6080.5-5476.3 ± 12816.5

Adverse events

Collected over 17 days after the first dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TNP-2092 Capsules 100mg Twice Daily(BID)0/8 (0%)0/8 (0%)6/8 (75%)
TNP-2092 Capsules 300mg BID0/8 (0%)0/8 (0%)6/8 (75%)
TNP-2092 Capsules 600mg BID0/8 (0%)0/8 (0%)7/8 (87.5%)
Placebo0/12 (0%)1/12 (8.3%)8/12 (66.7%)
Most frequent serious events
Most frequent serious events
EventTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDPlacebo
Gastrointestinal haemorrhageGastrointestinal disorders0/80/80/81/12
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDPlacebo
neutrophil count decreasedInvestigations2/84/86/86/12
white blood cell count decreasedInvestigations2/82/86/84/12
Lymphocyte count decreasedInvestigations1/82/84/82/12
Platelet count decreasedInvestigations3/81/80/85/12
Lipase increasedInvestigations3/80/80/80/12
HypoalbuminaemiaMetabolism and nutrition disorders2/82/81/82/12
Alanine aminotransferase increasedInvestigations0/82/80/80/12
Aspartate aminotransferase increasedInvestigations0/82/80/80/12
Blood fibrinogen decreasedInvestigations2/80/80/81/12
AnaemiaBlood and lymphatic system disorders1/81/80/82/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDTNP-2092 Capsules PlaceboTotal
<=18 years00000
Between 18 and 65 years8881236
>=65 years00000
Age, Continuous
Age, Continuous(years)TNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDTNP-2092 Capsules PlaceboTotal
Mean49.5 ± 7.1950.4 ± 5.7151.9 ± 7.9752.3 ± 10.1551.1 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)TNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDTNP-2092 Capsules PlaceboTotal
Female01348
Male875828
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDTNP-2092 Capsules PlaceboTotal
American Indian or Alaska Native00000
Asian8881236
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Fasting Venous Blood Ammonia Concentration
Fasting Venous Blood Ammonia Concentration(μmol/L)TNP-2092 Capsules 100mg Twice Daily(BID)TNP-2092 Capsules 300mg BIDTNP-2092 Capsules 600mg BIDTNP-2092 Capsules PlaceboTotal
Mean90.1 ± 27.180.3 ± 19.578.8 ± 17.3115.8 ± 39.194.0 ± 32.0
08

Study locations

1 site
  • The First Hospital of Jilin University
    Changchun, Jilin, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Jun 2021, 9 months.

Results were first posted in May 2024, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2023
First posted
Nov 18, 2023
StartActual
Aug 27, 2020
Primary completionActual
Jun 16, 2021
CompletionActual
Jun 16, 2021
Results first posted
May 10, 2024
Last update
Apr 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06135675
Lead sponsor
TenNor Therapeutics (Suzhou) Limited
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Aug 27, 2020
Primary completion
Jun 16, 2021
Completion
Jun 16, 2021
Results posted
May 10, 2024
Last update
Apr 25, 2025

Study contacts

Yanhua Ding, MD
principal investigator · The First Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TNP-2092

Start the discussion